|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics. CA Cancer J Clin. 60:277–300. 2010.
|
|
2
|
Yilmaz M and Christofori G: Mechanisms of
motility in metastasizing cells. Mol Cancer Res. 8:629–642. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shapiro SD: Matrix metalloproteinase
degradation of extracellular matrix: biological consequences. Curr
Opin Cell Biol. 10:602–608. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Decock J, Paridaens R and Ye S: Genetic
polymorphisms of matrix metalloproteinases in lung, breast and
colorectal cancer. Clin Genet. 73:197–211. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fingleton B: Matrix metalloproteinases:
roles in cancer and metastasis. Front Biosci. 11:479–491. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kessenbrock K, Plaks V and Werb Z: Matrix
metalloproteinases: regulators of the tumor microenvironment. Cell.
141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Airola K, Karonen T, Vaalamo M, et al:
Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and
-3 correlates with the level of invasion in malignant melanomas. Br
J Cancer. 80:733–743. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Heppner KJ, Matrisian LM, Jensen RA and
Rodgers WH: Expression of most matrix metalloproteinase family
members in breast cancer represents a tumor-induced host response.
Am J Pathol. 149:273–282. 1996.PubMed/NCBI
|
|
10
|
Hilska M, Roberts PJ, Collan YU, et al:
Prognostic significance of matrix metalloproteinases-1, -2, -7 and
-13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in
colorectal cancer. Int J Cancer. 121:714–723. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mori D, Nakafusa Y, Miyazaki K and
Tokunaga O: Differential expression of Janus kinase 3 (JAK3),
matrix metalloproteinase 13 (MMP13), heat shock protein 60 (HSP60),
and mouse double minute 2 (MDM2) in human colorectal cancer
progression using human cancer cDNA microarrays. Pathol Res Pract.
201:777–789. 2005. View Article : Google Scholar
|
|
12
|
Roeb E, Arndt M, Jansen B, Schumpelick V
and Matern S: Simultaneous determination of matrix
metalloproteinase (MMP)-7, MMP-1, -3, and -13 gene expression by
multiplex PCR in colorectal carcinomas. Int J Colorectal Dis.
19:518–524. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fang YJ, Lu ZH, Wang GQ, et al: Elevated
expressions of MMP7, TROP2, and survivin are associated with
survival, disease recurrence, and liver metastasis of colon cancer.
Int J Colorectal Dis. 24:875–884. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Leeman MF, McKay JA and Murray GI: Matrix
metalloproteinase 13 activity is associated with poor prognosis in
colorectal cancer. J Clin Pathol. 55:758–762. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Masaki T, Matsuoka H, Sugiyama M, et al:
Matrilysin (MMP-7) as a significant determinant of malignant
potential of early invasive colorectal carcinomas. Br J Cancer.
84:1317–1321. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yamada T, Oshima T, Yoshihara K, et al:
Overexpression of MMP-13 gene in colorectal cancer with liver
metastasis. Anticancer Res. 30:2693–2699. 2010.PubMed/NCBI
|
|
17
|
Ilvesaro JM, Merrell MA, Li L, et al:
Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular
invasion. Mol Cancer Res. 6:1534–1543. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ilvesaro JM, Merrell MA, Swain TM, et al:
Toll like receptor-9 agonists stimulate prostate cancer invasion in
vitro. Prostate. 67:774–781. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Merrell MA, Ilvesaro JM, Lehtonen N, et
al: Toll-like receptor 9 agonists promote cellular invasion by
increasing matrix metalloproteinase activity. Mol Cancer Res.
4:437–447. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nurmenniemi S, Kuvaja P, Lehtonen S, et
al: Toll-like receptor 9 ligands enhance mesenchymal stem cell
invasion and expression of matrix metalloprotease-13. Exp Cell Res.
316:2676–2682. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pfaffl MW: A new mathematical model for
relative quantification in real-time RT-PCR. Nucleic Acids Res.
29:e452001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hemmi H, Takeuchi O, Kawai T, et al: A
Toll-like receptor recognizes bacterial DNA. Nature. 408:740–745.
2000. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Latz E, Visintin A, Espevik T and
Golenbock DT: Mechanisms of TLR9 activation. J Endotoxin Res.
10:406–412. 2004. View Article : Google Scholar
|
|
24
|
Takeshita F, Gursel I, Ishii KJ, Suzuki K,
Gursel M and Klinman DM: Signal transduction pathways mediated by
the interaction of CpG DNA with Toll-like receptor 9. Semin
Immunol. 16:17–22. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen JM, Nelson FC, Levin JI, et al:
Structure-based design of a novel, potent, and selective inhibitor
for MMP-13 utilizing NMR spectroscopy and computer-aided molecular
desing. J Am Chem Soc. 122:9648–9654. 2000. View Article : Google Scholar
|
|
26
|
Koblinski JE, Ahram M and Sloane BF:
Unraveling the role of proteases in cancer. Clin Chim Acta.
291:113–135. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nelson AR, Fingleton B, Rothenberg ML and
Matrisian LM: Matrix metalloproteinases: biologic activity and
clinical implications. J Clin Oncol. 18:1135–1149. 2000.PubMed/NCBI
|
|
28
|
Stetler-Stevenson WG, Aznavoorian S and
Liotta LA: Tumor cell interactions with the extracellular matrix
during invasion and metastasis. Annu Rev Cell Biol. 9:541–573.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Deryugina EI and Quigley JP: Matrix
metalloproteinases and tumor metastasis. Cancer Metastasis Rev.
25:9–34. 2006. View Article : Google Scholar
|
|
30
|
Inoue A, Takahashi H, Harada H, et al:
Cancer stem-like cells of glioblastoma characteristically express
MMP-13 and display highly invasive activity. Int J Oncol.
37:1121–1131. 2010.PubMed/NCBI
|
|
31
|
Yong HY, Kim IY, Kim JS and Moon A:
ErbB2-enhanced invasiveness of H-Ras MCF10A breast cells requires
MMP-13 and uPA upregulation via p38 MAPK signaling. Int J Oncol.
36:501–507. 2010.PubMed/NCBI
|
|
32
|
Rath T, Roderfeld M, Graf J, et al:
Enhanced expression of MMP-7 and MMP-13 in inflammatory bowel
disease: a precancerous potential? Inflamm Bowel Dis. 12:1025–1035.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kawai T and Akira S: The role of
pattern-recognition receptors in innate immunity: update on
Toll-like receptors. Nat Immunol. 11:373–384. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bowman CC, Rasley A, Tranguch SL and
Marriott I: Cultured astrocytes express toll-like receptors for
bacterial products. Glia. 43:281–291. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Droemann D, Albrecht D, Gerdes J, et al:
Human lung cancer cells express functionally active Toll-like
receptor 9. Respir Res. 6:12005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Platz J, Beisswenger C, Dalpke A, et al:
Microbial DNA induces a host defense reaction of human respiratory
epithelial cells. J Immunol. 173:1219–1223. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Schmausser B, Andrulis M, Endrich S, et
al: Expression and subcellular distribution of toll-like receptors
TLR4, TLR5 and TLR9 on the gastric epithelium in Helicobacter
pylori infection. Clin Exp Immunol. 136:521–526. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Schmausser B, Andrulis M, Endrich S,
Muller-Hermelink HK and Eck M: Toll-like receptors TLR4, TLR5 and
TLR9 on gastric carcinoma cells: an implication for interaction
with Helicobacter pylori. Int J Med Microbiol. 295:179–185.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Coussens LM, Fingleton B and Matrisian LM:
Matrix metalloproteinase inhibitors and cancer: trials and
tribulations. Science. 295:2387–2392. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Parks WC, Wilson CL and Lopez-Boado YS:
Matrix metalloproteinases as modulators of inflammation and innate
immunity. Nat Rev Immunol. 4:617–629. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rath T, Roderfeld M, Graf J and Roeb E:
Matrix metalloproteinases in inflammatory bowel disease – from
basic research to clinical significance. Z Gastroenterol.
47:758–769. 2009.
|
|
42
|
Rath T, Roderfeld M, Halwe JM, Tschuschner
A, Roeb E and Graf J: Cellular sources of MMP-7, MMP-13 and MMP-28
in ulcerative colitis. Scand J Gastroenterol. 45:1186–1196.
2010.PubMed/NCBI
|
